Clinical trial · no report yet · Phase 3
LAP100
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06958328 ↗
- Recruiting
- NRG Oncology
- 69 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 56 | |
| X videos | 8 | |
| YouTube | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure; Biospecimen Collection; Capecitabine; Computed Tomography; Dose-escalated Radiation Therapy; Fluorouracil; Gemcitabine; Irinotecan Hydrochloride; Irinotecan Sucrosofate; Leucovorin Calcium; Magnetic Resonance Imaging; Nab-paclitaxel; Observation Activity; Oxaliplatin; Positron Emission Tomography; Questionnaire Administration; Radiation Therapy; Tumor Treating Fields Therapy
- Arms
- Arm I (Options 1, 2, or 3) · Active comparator
- Arm II (dose-escalated RT) · Experimental
- Enrollment
- 356 (estimated)
- Primary outcomes
- Overall survival (OS)
- Sponsor
- NRG Oncology
- Start
- Aug 21, 2025
- Primary completion
- Oct 21, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06958328 · updated Aug 25, 2026